期刊文献+

胺碘酮与普罗帕酮转复心房颤动疗效对比研究的系统评价 被引量:3

Systematic review of comparative study on the efficacy of amiodarone versus propafenone for the conversion of atrial fibrillation
下载PDF
导出
摘要 目的比较胺碘酮与普罗帕酮转复心房颤动(简称房颤)的疗效,为临床用药提供参考。方法计算机检索Cochrane图书馆(2008年第3期)、PubMed、EMBASE(荷兰医学文摘),中国生物医学文献数据库和中国知网全文数据库,收集2000年1月~2008年6月公开发表的有关比较胺碘酮与普罗帕酮转复房颤效果的文献,并用RevMan5.0统计软件对这些文献进行统计分析。结果共纳入5个随机对照试验,累计胺碘酮治疗组262例,普罗帕酮治疗组255例。胺碘酮与普罗帕酮转复房颤效果的合并OR值为1.26,95%可信区间为0.83~1.91,P>0.05。结论胺碘酮与普罗帕酮转复房颤的效果没有差异。 Objective To provide evidence for the clinic use of amiodarone and propafenone through investigating the efficacy of amiodarone versus propafenone for the conversion of atrial fibrillation. Method The Cochrane library( Issue 3, 2008) , PubMed, EMBASE, Chinese Biomedical Database and China National Knowledge Interact were searched. The literature comparing the efficacy of amiodarone versus propafenone for the conversion of atrial fibrillation, which were published between January 2000 and June 2008, were included. Meta-analysis was performed using RevMan 5.0 software. Results Five randomized controlled trails (RCT) were identified. The amiodarone and propafenone cases were 262 and 255, respectively. The pooled odds ratio ( OR ) values and 95% confidence interval were 1.26,0.83 - 1.91 respectively, P 〉 0.05. Conclusions There is no significant difference between the efficacy of amiodarone and that of propafenone for the conversion of atrial fibrillation.
出处 《中国心脏起搏与心电生理杂志》 北大核心 2009年第2期122-126,共5页 Chinese Journal of Cardiac Pacing and Electrophysiology
关键词 心血管病学 心房颤动 胺碘酮 普罗帕酮 系统评价 Cardiology Atrial fibrillation Amiodarone Propafenone Systematic review
  • 相关文献

参考文献7

  • 1Fuster V, Ryden LE, Cannomand DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary[J]. Euro Heart J, 2006,27:1 979
  • 2Alejandro R, Jadad R,Moore A, et al. Assessing the quality of reports of randomized clinical trials : Is blinding necessary [ J ] .9 Controlled Clin TriMs, 1996 , 17(1) : 1
  • 3Martlnez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm [ J ]. Am J Cardial,2000, 86:950
  • 4Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation [J]. Am J Cardiol,2007, 99:1 721
  • 5谢陈玲,宋晓蓉.口服胺碘酮和心律平治疗心房纤颤疗效比较[J].四川生理科学杂志,2006,28(3):134-135. 被引量:3
  • 6邹桂和,李红阳.胺碘酮与普罗帕酮治疗房颤的疗效对比分析[J].中国医药导刊,2004,6(1):45-46. 被引量:11
  • 7马丹,刘凤岐,富路,李元十,高倩平,吴炳祥.口服普罗帕酮与胺碘酮联合电复律转复持续性房颤的随机对照试验[J].中国循证医学杂志,2007,7(3):165-168. 被引量:6

二级参考文献24

  • 1胡琛.胺碘酮抗心律失常的新认识[J].国外医药(合成药.生化药.制剂分册),1996,17(2):91-94. 被引量:2
  • 2张旭明.心律失常[A].叶任高主编.内科学(第五版)[C].北京:人民卫生出版社,2000(11).172—218.
  • 3[3]Ui G,Sen L,Sager P.Effects of amiodarone,senatilide,and sotalol on QT dispersion[J].Am J Cardiol,1994; 74:896-899.
  • 4[4]Connolly SJ.Meta-analysis of antiarrhythmic drug trials[J].Am J Cardiol 1999;84(9A):90-93.
  • 5Chatelain P, Gremel M , Brotelle R. Prevention by amiodarnone of phospholipid depletion in isoproterend - induced ischemia in mt.Eur J Pharmacol, 1987; 144:83 - 90.
  • 6Shaikh NA . Effect of amiodarnone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischemia in cat hears. J Mol Cardiol. 1992:24:507 - 521.
  • 7Deedwania PC , Singh BN, Ellenbogen K, et al . Spontanous conversion and maintenance of sinus rhythm by amiodamone in patients with heart failure and atrial fibrillation: observatiom from the veterans affairs congestive heart failure survival trial of antitmhyttmctherapy (CHF - STAT). Circulation, 1998;98(23) :2574-2579.
  • 8Hohnloser SH , Van de Loo A , Kalusche D, et al. Dose sotalol- induced alteration of QT dispersion predict drug effctiveness or proarrhythmic hazards (Abstract) . Circulation, 1993;88:397.
  • 9Gillis AM, Traboulsi M, Wyse DG, et al. Dispersion of ventricular reploarization predicts antiarrhythmic drug response (Abstract).Circulation, 1993; 88:395.
  • 10Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation, 2004, 109(16):1973-1980.

共引文献15

同被引文献26

  • 1中国生物医学工程学会心律分会.中国医师协会心血管内科医师分会,中国医药生物技术协会心电学技术分会,伊布利特临床应用中国专家共识.中国心脏起搏与心电生理杂志,2011,.
  • 2Fuster V, Rydrn LE, Ca nnom DS, et al. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: full text: a report of American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guideline (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [J]. Europace, 2006, 8(9): 651-745.
  • 3Camm AJ, Kirchhof P, Lip GY, et al. Guideline for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2010,31 (19) 2369-429.
  • 4Warm LS, Curtis AB, January CT, et al. 2011 ACCF/ AHA/HRS focused update on the management of patients with atrial fibrillation(updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation, 2011, 123(1): 104-23.
  • 5Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation[J]. Int J Cardiol, 2008, 127(3): 299-306.
  • 6Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure [J]. N Engl J Med, 2008, 358(25): 2667-77.
  • 7Corley SD, Epstein AE, DiMacro JP, et al. Relationships between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow -Up Investigation of Rhythm Management (AFFIRM) study [J]. Circulation, 2004, 109(12): 1509-13.
  • 8Cioffi G, de Feo S, Pulignano G, et al. Does atial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? [J] Int J Cardiol, 2006, 107(2): 220- 4.
  • 9Pritchett EL Page RL, Carlson M, et al. Efficacy and safety of sustained-release propafenone for patients with atrial fibrillation[J]. Am J Cardiol, 2003, 92(8): 941--6.
  • 10Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin system: a therapeutic target in atrial fibrillation [J]. Pacing Clin Electrophysiol, 2006, 29 (9): 1006- 12.

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部